Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Patient Reported Outcomes ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Carcinoma Patient ◽

Patient Reported ◽

A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps4153 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS4153-TPS4153 ◽

Cited By ~ 8

Author(s):

Richard S. Finn ◽

Ann-Lii Cheng ◽

Kenji Ikeda ◽

Masatoshi Kudo ◽

Toshiyuki Tamai ◽

...

Keyword(s):

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress

Annals of Oncology ◽

10.1093/annonc/mdy151.181 ◽

2018 ◽

Vol 29 ◽

pp. v51

Author(s):

S. Qin ◽

R. Finn ◽

M. Kudo ◽

T. Meyer ◽

A. Vogel ◽

...

Keyword(s):

Multicenter Study ◽

Study Trial ◽

Advanced Hepatocellular Carcinoma ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps3110 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS3110-TPS3110 ◽

Cited By ~ 8

Author(s):

Shukui Qin ◽

Richard S. Finn ◽

Masatoshi Kudo ◽

Tim Meyer ◽

Arndt Vogel ◽

...

Keyword(s):

Multicenter Study ◽

Advanced Hepatocellular Carcinoma ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps4144 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS4144-TPS4144 ◽

Cited By ~ 29

Author(s):

Ghassan K. Abou-Alfa ◽

Stephen Lam Chan ◽

Junji Furuse ◽

Peter R. Galle ◽

Robin Kate Kelley ◽

...

Keyword(s):

Line Treatment ◽

First Line ◽

Phase 3 ◽

Multicenter Phase ◽

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

The Lancet ◽

10.1016/s0140-6736(18)30207-1 ◽

2018 ◽

Vol 391 (10126) ◽

pp. 1163-1173 ◽

Cited By ~ 881

Author(s):

Masatoshi Kudo ◽

Richard S Finn ◽

Shukui Qin ◽

Kwang-Hyub Han ◽

Kenji Ikeda ◽

...

Keyword(s):

Line Treatment ◽

First Line ◽

Phase 3 ◽

Faculty Opinions recommendation of Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732647407.793574886 ◽

2020 ◽

Author(s):

Man-Fung Yuen ◽

Lung-Yi Mak

Keyword(s):

Line Treatment ◽

First Line ◽

Phase 3 ◽

Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)

Annals of Oncology ◽

10.1093/annonc/mdx440.022 ◽

2017 ◽

Vol 28 ◽

pp. v617 ◽

Cited By ~ 6

Author(s):

R.S. Finn ◽

M. Kudo ◽

A-L. Cheng ◽

L. Wyrwicz ◽

R. Ngan ◽

...

Keyword(s):

Serum Biomarkers ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00151-0 ◽

2021 ◽

Cited By ~ 1

Author(s):

Peter R Galle ◽

Richard S Finn ◽

Shukui Qin ◽

Masafumi Ikeda ◽

Andrew X Zhu ◽

...

Keyword(s):

Patient Reported Outcomes ◽

Open Label ◽

Phase 3 ◽

Patient Reported

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Multicenter Phase ◽